Because the tumor possessed two geographically distinct areas of PXA versus epithelioid neuronal tumor, samples could be tested separately and confidently from these two differing areas of tumor for BRAF V600E mutational status. The gene discussed is BRAF; the disease is pleomorphic xanthoastrocytoma.